CCL2抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P03800(CCL2 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The CCL2 antibody targets CCL2 (C-C motif chemokine ligand 2), a small cytokine belonging to the CC chemokine family, also known as monocyte chemoattractant protein-1 (MCP-1). CCL2 plays a critical role in recruiting monocytes, memory T cells, and dendritic cells to sites of inflammation by binding to its receptor CCR2. It is implicated in chronic inflammatory diseases, autoimmune disorders, cancer progression, and atherosclerosis due to its role in promoting immune cell infiltration and tissue remodeling. Dysregulated CCL2 expression is associated with pathological conditions, making it a therapeutic target.

CCL2 antibodies are designed to neutralize CCL2 activity, blocking its interaction with CCR2 and downstream signaling pathways. These antibodies are used as research tools to study CCL2-mediated mechanisms in disease models and have been explored as potential therapeutics. Preclinical studies demonstrate that CCL2 inhibition reduces inflammation, tumor growth, and metastasis. However, clinical trials targeting the CCL2/CCR2 axis in diseases like cancer or fibrosis have shown mixed results, highlighting complexities in pathway redundancy and compensatory mechanisms. Despite challenges, CCL2 antibodies remain a focus for developing treatments aimed at modulating immune responses in inflammatory and neoplastic diseases.